A Phase 4 interventional study of leuprolide acetate in Cancer of Prostate, sponsored by San Bernardino Urological Associates Medical Group Inc. Completed at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-14.
Sponsored by San Bernardino Urological Associates Medical Group Inc · Phase 4, Interventional, and Treatment
Comparing the effect of switching from Lupron and Zoladex to Eligard. PSA and Testosterone levels are measured at set intervals to determine if Eligard is equal or better then Lupron or Zoladex in advanced Prostate Cancer patients.
6,370 studies on the registry are indexed under Prostatic Neoplasms; 1,400 are open to participants now.
This study's enrollment of 100 is above the median of 58 across 4,822 interventional studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →This is the only study on the registry with San Bernardino Urological Associates Medical Group Inc as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria: Patient with Advanced Ca, on stable dose of Lupron or Zoladex
-
Exclusion Criteria:
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.